irinotecan liposome + cetuximab + bevacizumab

This is a **combination regimen** of three drugs: **irinotecan liposome**, **cetuximab**, and **bevacizumab**. - **Irinotecan liposome** is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. Encapsulation in liposomes improves the pharmacokinetics, prolongs half-life, enhances tumor accumulation via the enhanced permeability and retention (EPR) effect, and reduces systemic toxicity compared to free irinotecan. - **Cetuximab** is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting cell proliferation and survival in EGFR-expressing tumor cells. - **Bevacizumab** is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis and reducing tumor blood supply. This combination is being investigated in various cancers, particularly metastatic colorectal cancer and pancreatic adenocarcinoma, where each component provides a complementary anti-tumor effect via distinct mechanisms.

Other names

Irinotecan Liposomes (II) + Cetuximab + BevacizumabIrinotecan Liposome (II) + Cetuximab + Bevacizumab